HonorHealth Research Institute, University of Arizona College of Medicine Scottsdale, AZ
Medical Oncology/Clinical Investigator Clinical Assistant Professor, Internal Medicine
Dr. Borazanci is a medical oncologist and clinical investigator at the Virginia G. Piper Cancer Center at HonorHealth Research Institute. Dr. Borazanci is also the medical director of the molecular medicine institute at HonorHealth and holds adjunct appointments as clinical assistant professor at the Translational Genomics Research Institute (TGen) and University of Arizona. Dr. Borazanci obtained his masters of science in molecular biology and biochemistry at Louisiana State University Health. He completed medical school, internal medicine, and oncology fellowship at LSU Health Shreveport and was recruited as the drug development scholar from 2013 to 2015. His specialty is gastrointestinal oncology, particularly pancreatic cancer, and has had the privilege to work closely with leaders in the field including Dr. Dan Von Hoff and Dr. Ramesh Ramanathan. He was invited to the 2014 AACR/ASCO Workshop Methods in Clinical Cancer Research. Dr. Borazanci is the principal investigator for several clinical trials, many of which are Phase I and are first in human studies. HonorHealth Research Institute has closely worked with TGen along with several collaborators to bring new and promising agents to offer as treatment options at the Virginia G. Piper Cancer Center on the HonorHealth Shea Campus. He is Board Certified by the American Board of Internal Medicine.
1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980
2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.
3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680
4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)
5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997. https://www.jbc.org
6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org